Warnex Inc.

Warnex Inc.

November 16, 2006 16:30 ET

Notice - Typographical correction to Warnex third quarter 2006 French financial statements

LAVAL, QC, Nov. 16 - Warnex Inc. ("Warnex") (TSX: WNX) today
announced that it has made a correction to a typographical error in its third
quarter 2006 French financial statements in the press release and as posted on
SEDAR on November 9th, 2006. The typographical error occurred during the
translation from English to French of the Interim Consolidated Statements of
Cash Flows on the Acquisition of property, plant and equipment line
("Acquisition d'immobilisations corporelles") under column heading Three
months ended September 30, 2006 ("Trois mois terminés le 30 septembre 2006").
The original number reported in the French statements was $(1,236,636) and
should have been $(1,238,636) to reflect the English. The column's total was
not affected. The English statements in the English press release and posted
on SEDAR dated November 9, 2006, were correct and have not been re-filed.

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
DNA-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing and meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and medical laboratory service groups
offer a variety of quality control services, method development and
validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, integration of acquisitions, manufacturing and
laboratory facilities, suppliers, key employees, key customers and business
partners, financial resources and credit risk, government regulations, foreign
currency risk and volatility of share price, and other important factors that
could cause actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and
Uncertainties in the Management's Discussion and Analysis for the third
quarter ended September 30, 2006, which can be found at www.sedar.com.
Consequently, actual results may differ materially from the anticipated
results expressed in these forward-looking statements.

Contact Information